{"transactions":[{"id":2664126,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T19:26:49.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested."}],"balance_after":10000,"derivative":{"exercise_price":35.26,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919121041713/doc4.xml","form_type":"4"}},{"id":2664125,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T19:26:49.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":10000,"derivative":{"exercise_price":35.26,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919121041713/doc4.xml","form_type":"4"}},{"id":3003157,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":71427,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71427},"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003156,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":245966,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":245966},"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003155,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1434790,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1434790},"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003154,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":3698,"ownership":{"direct":false,"nature":"By Tester Living Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3698},"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003153,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":21575,"ownership":{"direct":false,"nature":"By Tester Living Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21575},"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003152,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":168750,"price":16,"value":2700000.0,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":1920933,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003151,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":71427,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":1752183,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003150,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":245966,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":1680756,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003149,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1434790,"ownership":{"direct":false,"nature":"By Horowitz Limited Partnership VIII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Horowitz Limited Partnership VIII.  The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII.  The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":1434790,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003148,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":3125,"price":16,"value":50000.0,"ownership":{"direct":false,"nature":"By Tester Living Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares."}],"balance_after":28398,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003147,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":3698,"ownership":{"direct":false,"nature":"By Tester Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares."}],"balance_after":25273,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}},{"id":3003146,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":138133,"kind":"person","name":"Tester Jason E.","position":1,"cik":"0001827272","reported_name":"Tester Jason E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T19:56:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":21575,"ownership":{"direct":false,"nature":"By Tester Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares."}],"balance_after":21575,"source":{"system":"sec-edgar","filing":"0001209191-20-055421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827272/000120919120055421/doc4.xml","form_type":"4"}}]}